NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma | GSK

GlaxoSmithKline plc (GSK) today announced publication of results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study, VESTRI (SAS115358) in the New England Journal of Medicine (NEJM). Headline results reported in March, demonstrated that the study had achieved its primary endpoint. The study compared Advair® Diskus®, a combination of the LABA, salmeterol and inhaled corticosteroid (ICS), fluticasone propionate (FP) to FP monotherapy, to assess the safety profiles of each medicine when used to treat children 4-11 years of age with asthma. This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations). These results are also being presented at the European Respiratory Society (ERS) International Congress in London, UK on 7th September, (Abstract number: OA4798).



NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma | GSK